James P Yee Net Worth

The estimated Net Worth of James P Yee is at least $2.96 Million dollars as of 1 July 2019. James Yee owns over 20,000 units of Caredx Inc stock worth over $1,199,544 and over the last 10 years James sold CDNA stock worth over $1,756,398.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

James Yee CDNA stock SEC Form 4 insiders trading

James has made over 5 trades of the Caredx Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently James sold 20,000 units of CDNA stock worth $713,000 on 1 July 2019.

The largest trade James's ever made was selling 32,500 units of Caredx Inc stock on 12 February 2019 worth over $776,100. On average, James trades about 4,968 units every 26 days since 2015. As of 1 July 2019 James still owns at least 42,045 units of Caredx Inc stock.

You can see the complete history of James Yee stock trades at the bottom of the page.

What's James Yee's mailing address?

James's mailing address filed with the SEC is C/O CAREDX, INC., 3260 BAYSHORE BOULEVARD, BRISBANE, CA, 94005.

Insiders trading at Caredx Inc

Over the last 10 years, insiders at Caredx Inc have traded over $60,271,359 worth of Caredx Inc stock and bought 1,726,634 units worth $9,072,700 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Neil Gagnon, and Peter Maag. On average, Caredx Inc executives and independent directors trade stock every 17 days with the average trade being worth of $615,506. The most recent stock trade was executed by Alexander L Johnson on 20 August 2024, trading 61,023 units of CDNA stock currently worth $1,432,820.

What does Caredx Inc do?

caredx: transforming transplant patient care through novel surveillance management solutions caredx, inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. by combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, caredx is at the forefront of organ transplant surveillance and pre-transplant hla typing solutions. nasdaq:cdna about allosure® allosure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. allosure is a clinical-grade, proprietary next-generation sequencing (ngs) based test to detect donor-derived cell-free dna (dd-cfdna) in order to identify organ injury in kidney transplant recipients. allosure is analytically validated as a sensitive, specific, and precise measurement of dd-cfdna. allos

Complete history of James Yee stock trades at Caredx Inc

Caredx Inc executives and stock owners

Caredx Inc executives and other stock owners filed with the SEC include:

• Peter Maag,
  Executive Chairman of the Board of Directors
• Michael Bell,
  Chief Financial Officer
• Reginald Seeto,
  President, Chief Executive Officer, Director
• Dr. Peter Maag Ph.D.,
  Exec. Director
• Sasha King,
  Chief Marketing Officer
• Alexander L. Johnson,
  Pres of Patient and Testing Services
• Sasha King M.B.A.,
  Chief Marketing Officer & Franchise Head of Kidney Transplant
• Marcel Konrad,
  Sr. VP of Fin. and Accounting & Corp. Controller
• Michael Goldberg,
  Lead Independent Director
• Grace Colon,
  Independent Director
• Christine Cournoyer,
  Independent Director
• Ralph Snyderman,
  Independent Director
• George Bickerstaff,
  Independent Director
• Frederick Cohen,
  Independent Director
• William Hagstrom,
  Independent Director
• David Clair,
  IR Contact Officer
• Marica Grskovic Ph.D.,
  Chief Operating Officer
• Abhishek Jain,
  CFO, VP, Corp. Controller, Principal Financial Officer & Principal Accounting Officer
• Dr. Mickey Y. Kim M.D.,
  Sr. VP of Corp. Devel. & Strategy
• Abraham Ronai Esq.,
  Gen. Counsel, Chief Admin. & Legal Officer and Sec.
• Ian Cooney,
  VP of Investor Relations
• Amitabh Shukla,
  Sr. VP of Technology
• Paul Ciccolella,
  Sr. VP of Global Operations
• Ankur Dhingra,
  Chief Financial Officer
• Charles Constanti,
  Chief Financial Officer
• Douglas S Miller,
  Director
• Todd Whitson,
  Chief Commercial Officer
• Brook H Byers,
  Director
• John Joseph Sninsky,
  Chief Scientific Officer
• James P Yee,
  Chief Medical Officer
• Neil Gagnon,
  10% owner
• Mitchell J Nelles,
  Chief Operating Officer
• Anders Karlsson,
  See Remarks
• Richard Bryan Riggsbee,
  Director
• Amy Abernethy,
  Director
• Fred E Cohen,
  
• Ken Ludlum,
  Chief Financial officer
• Matthew J. Meyer,
  Chief Business Officer
• Joshua De Fonzo,
  Chief Commercial Officer
• Perkins Caufield & Byers X ...,
  
• Group Holdings (Sbs) Adviso...,
  
• Abraham Ronai,
  See Remarks
• Abhishek Jain,
  Chief Financial Officer
• Ankur Dhingra,
  Chief Financial Officer
• Hannah Valantine,
  
• Arthur A Torres,
  
• Alexander L Johnson,
  See Remarks
• Jeffrey Adam Novack,
  Secretary and General Counsel